SO
ELVN icon

STRS Ohio’s Enliven Therapeutics ELVN Stock Holding History

STRS Ohio’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Buy
+5,600
New +$238K ﹤0.01% 1427
2025
Q1 		– Sell
-1,200
Closed -$27K – 1960
2024
Q4 		$27K Hold
1,200
– – ﹤0.01% 1788
2024
Q3 		$30.6K Buy
+1,200
New +$27.8K ﹤0.01% 1864
2021
Q1 		– Sell
-325
Closed -$28K – 2198
2020
Q4 		$28K Hold
325
– – ﹤0.01% 2054
2020
Q3 		$26K Hold
325
– – ﹤0.01% 2058
2020
Q2 		$35K Buy
+325
New +$36.4K ﹤0.01% 1963

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

STRS Ohio's ELVN Position: Q2 2026 in Review

STRS Ohio opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 5,600 shares worth $284K. The stake represents ﹤0.01% of the portfolio and ranks #1427 among its holdings. This is a return to the name: STRS Ohio previously reported a position in ELVN as recently as Q4 2024.

STRS Ohio first reported a position in ELVN in Q2 2020 and has held it in 6 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • STRS Ohio held 5,600 shares of Enliven Therapeutics worth $284K as of Q2 2026.
  • Enliven Therapeutics was a new STRS Ohio position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1427 holding.
  • STRS Ohio first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.